Cargando…
Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?
Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712482/ https://www.ncbi.nlm.nih.gov/pubmed/33228010 http://dx.doi.org/10.3390/jof6040300 |
_version_ | 1783618383844999168 |
---|---|
author | do Carmo Silva, Lívia de Oliveira, Amanda Alves de Souza, Dienny Rodrigues Barbosa, Katheryne Lohany Barros Freitas e Silva, Kleber Santiago Carvalho Júnior, Marcos Antonio Batista Rocha, Olívia Basso Lima, Raisa Melo Santos, Thaynara Gonzaga Soares, Célia Maria de Almeida Pereira, Maristela |
author_facet | do Carmo Silva, Lívia de Oliveira, Amanda Alves de Souza, Dienny Rodrigues Barbosa, Katheryne Lohany Barros Freitas e Silva, Kleber Santiago Carvalho Júnior, Marcos Antonio Batista Rocha, Olívia Basso Lima, Raisa Melo Santos, Thaynara Gonzaga Soares, Célia Maria de Almeida Pereira, Maristela |
author_sort | do Carmo Silva, Lívia |
collection | PubMed |
description | Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM. |
format | Online Article Text |
id | pubmed-7712482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77124822020-12-04 Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? do Carmo Silva, Lívia de Oliveira, Amanda Alves de Souza, Dienny Rodrigues Barbosa, Katheryne Lohany Barros Freitas e Silva, Kleber Santiago Carvalho Júnior, Marcos Antonio Batista Rocha, Olívia Basso Lima, Raisa Melo Santos, Thaynara Gonzaga Soares, Célia Maria de Almeida Pereira, Maristela J Fungi (Basel) Review Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM. MDPI 2020-11-19 /pmc/articles/PMC7712482/ /pubmed/33228010 http://dx.doi.org/10.3390/jof6040300 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review do Carmo Silva, Lívia de Oliveira, Amanda Alves de Souza, Dienny Rodrigues Barbosa, Katheryne Lohany Barros Freitas e Silva, Kleber Santiago Carvalho Júnior, Marcos Antonio Batista Rocha, Olívia Basso Lima, Raisa Melo Santos, Thaynara Gonzaga Soares, Célia Maria de Almeida Pereira, Maristela Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? |
title | Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? |
title_full | Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? |
title_fullStr | Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? |
title_full_unstemmed | Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? |
title_short | Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? |
title_sort | overview of antifungal drugs against paracoccidioidomycosis: how do we start, where are we, and where are we going? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712482/ https://www.ncbi.nlm.nih.gov/pubmed/33228010 http://dx.doi.org/10.3390/jof6040300 |
work_keys_str_mv | AT docarmosilvalivia overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT deoliveiraamandaalves overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT desouzadiennyrodrigues overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT barbosakatherynelohanybarros overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT freitasesilvaklebersantiago overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT carvalhojuniormarcosantoniobatista overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT rochaoliviabasso overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT limaraisamelo overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT santosthaynaragonzaga overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT soaresceliamariadealmeida overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing AT pereiramaristela overviewofantifungaldrugsagainstparacoccidioidomycosishowdowestartwhereareweandwherearewegoing |